Streetbeat News

Analyst Ratings

ONTF

Canaccord Genuity analyst David Hynes maintains a Hold rating on ON24 (NYSE:ONTF) and lowers the price target from $10 to $9.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 3:01 pm

ALRM

Recent analyst ratings for Alarm.com Holdings (NASDAQ:ALRM) show a mix of perspectives, with a shift towards a more neutral stance in the last 30 days. Analysts have raised their 12-month price targets, indicating a 10.4% increase from the previous average, with a new average target of $69.00. The company's financial performance is strong, with notable revenue growth, high net margin, and efficient asset management. Alarm.com Holdings operates in cloud-based software for connected properties and generates most of its revenue through SaaS and license fees, primarily in the United States and Canada.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 3:01 pm

RVLV

Seven financial analysts have recently updated their ratings on Revolve Group (NYSE:RVLV), showing a mix of bullish to bearish sentiments. The average 12-month price target is now $18.00, up from $16.50, indicating a positive outlook. Analysts from firms like Stifel, Piper Sandler, and Goldman Sachs have adjusted their price targets and ratings, reflecting changes in market conditions and Revolve Gr's performance. Despite this, Revolve Gr faces challenges with a revenue decline of -4.13% over the last three months, below-average net margin, and ROE, suggesting potential hurdles ahead.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 3:01 pm

CART

Deep-pocketed investors have shown a bullish sentiment towards Maplebear (NASDAQ:CART), with a significant move in options trading observed. Benzinga's options scanner revealed 9 extraordinary activities, with 77% of investors leaning bullish. The expected price range for CART is between $29.5 to $37.0 over the next three months. The largest trades include bullish calls with strike prices ranging from $31.00 to $33.00. Maplebear, doing business as Instacart, has seen its stock price increase by 3.61% to $30.96. Analysts have mixed views, with an average target price of $34.5.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 3:01 pm

LLY

Eli Lilly and Co (NYSE:LLY) has seen significant options market activity, with a bearish sentiment prevailing among big-money investors. Benzinga's options scanner revealed 21 unusual trades, with a split sentiment of 38% bullish and 61% bearish. The trades suggest a price window of $520 to $1160 for LLY. The company, a drug firm focusing on various therapeutic areas, is currently trading at $775.86, up 0.81%, but may be overbought according to RSI readings. Analysts have issued mixed ratings, with a consensus target price of $741.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 3:01 pm

HCAT

Health Catalyst (NASDAQ:HCAT) has received mixed analyst ratings over the last three months, with 2 bullish and 3 somewhat bullish ratings. The average 12-month price target for HCAT has been raised to $11.8, up from $11.50. Analysts from Canaccord Genuity, Guggenheim, Evercore ISI Group, Piper Sandler, and JP Morgan have adjusted their ratings and price targets, reflecting diverse perspectives on the company's performance and market position. Health Catalyst's financial health indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management are also highlighted, showcasing the company's strengths and areas of concern.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 3:00 pm

MRNA

Analyst ratings for Moderna (NASDAQ:MRNA) have varied over the last quarter, with recent updates showing a mix of 'Hold' and 'Outperform' ratings. The average 12-month price target has risen to $106.0, a 21.14% increase from the previous $87.50, indicating a positive outlook. Moderna's financials reveal challenges, including a -44.5% revenue decline and below-average net margin and ROE. Despite this, its mRNA technology and diverse clinical trial programs position it as a key player in biotech.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 3:00 pm

SKWD

Seven financial analysts have recently updated their ratings and price targets on Skyward Specialty (NASDAQ:SKWD), showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target for SKWD has been raised to $39.29 from $36.50, indicating a positive outlook on the company's performance. Skyward Specialty, a specialty insurance company, has shown positive revenue growth but faces challenges in net margin and competes in a tough financial sector. Despite these challenges, its ROE and ROA outperform industry averages, and it maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 3:00 pm

SQ

Block (NYSE:SQ), also known as Square, saw its stock surge over 20% following its Q4 earnings report, which included a revenue surprise of 1.28% but an EPS miss by 23.73%. CEO Jack Dorsey highlighted cost reductions and a focus on growth. JPMorgan analyst Tien-tsin Huang maintains an Overweight rating on SQ with a $90 price target, citing strong Cash App momentum and potential from expanding banking services. Block's FY24 outlook anticipates over 15% gross profit growth, with innovations like a 'pay-as-you-go' model and bundled restaurant offerings seen as additional growth catalysts.

Portfolio Pulse from Surbhi Jain

February 23, 2024 | 2:55 pm

NTLA

Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Intellia Therapeutics (NTLA) and raises the price target from $72 to $73.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 2:54 pm